Harper; Steven
Patent Applications and Registrations
Patent applications and USPTO patent grants for Harper; Steven.The latest application filed is for "compounds for use in the treatment of kinetoplastid infection".
Company Profile
3.19.23
- Harper; Steven - Pomezia IT
- HARPER; Steven - Pomezia RM
- Harper; Steven - Rome IT
- Harper; Steven - Ariccia IT
- Harper; Steven - Fanwood NJ
- HARPER; STEVEN - TINTERN GWENT GB
- Harper; Steven - Chepstow GB
- Harper; Steven - Pomezia Rome
- Harper; Steven - Albano Laziale Rome
- Harper; Steven - Albano Laziale IT
Patent Activity
| Patent | Date |
|---|---|
| Compounds for use in the treatment of kinetoplastid infection Grant 10,815,222 - Biancofiore , et al. October 27, 2 | 2020-10-27 |
| Compounds For Use In The Treatment Of Kinetoplastid Infection App 20200095232 - BIANCOFIORE; Ilaria ; et al. | 2020-03-26 |
| Cyclic phosphates and cyclic phosphoramidates for the treatment of neurologic disorders Grant 10,364,263 - Beconi , et al. | 2019-07-30 |
| Cyclic Phosphates And Cyclic Phosphoramidates For The Treatment Of Neurologic Disorders App 20180362564 - Beconi; Maria ; et al. | 2018-12-20 |
| HCV NS3 protease inhibitors Grant 9,738,661 - Liverton , et al. August 22, 2 | 2017-08-22 |
| Compounds for use in the treatment of disorders that are ameliorated by inhibition of HDAC Grant 9,371,295 - Altamura , et al. June 21, 2 | 2016-06-21 |
| Compounds for use in the treatment of parasitic diseases Grant 9,365,541 - Altamura , et al. June 14, 2 | 2016-06-14 |
| HCV NS3 protease inhibitors Grant 9,328,138 - Rudd , et al. May 3, 2 | 2016-05-03 |
| Compounds For Use In The Treatment Of Parasitic Diseases App 20150299163 - ALTAMURA; Sergio ; et al. | 2015-10-22 |
| HCV NS3 Protease Inhibitors App 20150266897 - Liverton; Nigel J. ; et al. | 2015-09-24 |
| Compounds For Use In The Treatment Of Disorders That Are Ameliorated By Inhibition Of Hdac App 20150218112 - Altamura; Sergio ; et al. | 2015-08-06 |
| Macrocyclic compounds as antiviral agents Grant 8,927,569 - Harper , et al. January 6, 2 | 2015-01-06 |
| Hcv Ns3 Protease Inhibitors App 20140296136 - Rudd; Michael T. ; et al. | 2014-10-02 |
| Therapeutic compounds Grant 8,591,878 - McCauley , et al. November 26, 2 | 2013-11-26 |
| Macrocyclic compounds as antiviral agents Grant 8,314,062 - Crescenzi , et al. November 20, 2 | 2012-11-20 |
| Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors Grant 8,080,654 - Harper , et al. December 20, 2 | 2011-12-20 |
| Macrocyclic Quinoxaline Compounds As Hcv Ns3 Protease Inhibitors App 20110224134 - Harper; Steven ; et al. | 2011-09-15 |
| Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors Grant 7,973,040 - Harper , et al. July 5, 2 | 2011-07-05 |
| Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection Grant 7,879,815 - MacCoss , et al. February 1, 2 | 2011-02-01 |
| Therapeutic Compounds App 20110002884 - McCauley; John A. ; et al. | 2011-01-06 |
| Growth Factor Isoform App 20100305034 - BATES; DAVID ; et al. | 2010-12-02 |
| VEGF isoforms and their use as anti-angiogenic, anti-vasodilatory, anti-permeability and anti-proliferative agents Grant 7,820,178 - Bates , et al. October 26, 2 | 2010-10-26 |
| Nucleoside Aryl Phosphoramidates for the Treatment of RNA-Dependent RNA Viral Infection App 20100234316 - MacCoss; Malcolm ; et al. | 2010-09-16 |
| Macrocyclic Compounds As Antiviral Agents App 20100183551 - Harper; Steven ; et al. | 2010-07-22 |
| HCV NS3 Protease Inhibitors App 20100099695 - Liverton; Nigel J. ; et al. | 2010-04-22 |
| Macrocyclic Quinoxaline Compounds as HCV NS3 Protease Inhibitors App 20100029666 - Harper; Steven ; et al. | 2010-02-04 |
| Macrocyclic Compounds as Antiviral Agents App 20090312241 - Crescenzi; Benedetta ; et al. | 2009-12-17 |
| Tetracyclic Indole Derivatives as Antiviral Agents App 20090136449 - Di Filippo; Marcello ; et al. | 2009-05-28 |
| Dihydroxypyrimidine carboxamide inhibitors of HIV integrase Grant 7,459,452 - Di Francesco , et al. December 2, 2 | 2008-12-02 |
| Indole acetamides as inhibitors of the hepatitis c virus ns5b polymerase App 20070167447 - Avolio; Salvatore ; et al. | 2007-07-19 |
| Dihydroxypyrimidine carboxamide inhibitors of HIV integrase Grant 7,232,819 - Di Francesco , et al. June 19, 2 | 2007-06-19 |
| Dihydroxypyrimidine carboxamide inhibitors of HIV integrase App 20070083045 - Di Francesco; Maria E. ; et al. | 2007-04-12 |
| Indoles and azaindoles as antiviral agents App 20070072911 - Avolio; Salvatore ; et al. | 2007-03-29 |
| Peptides and their use as inhibitors of hepatitis C virus ns3 protease Grant 7,119,073 - Colarusso , et al. October 10, 2 | 2006-10-10 |
| Dihydroxypyridmidine carboxylic acids as viral polymerase inhibitors Grant 7,091,209 - Gardelli , et al. August 15, 2 | 2006-08-15 |
| Pyrimidinone viral polymerase inhibitors App 20050130997 - Avolio, Salvatore ; et al. | 2005-06-16 |
| Dihydroxypyrimidine carboxamide inhibitors of hiv integrase App 20050075356 - Di Francesco, Maria E. ; et al. | 2005-04-07 |
| Growth factor isoform App 20050054036 - Bates, David ; et al. | 2005-03-10 |
| Peptides and their use as inhibitors of hepatitis c virus ns3 protease App 20040142876 - Colarusso, Stefania ; et al. | 2004-07-22 |
| Dihydroxypyrimidine carboxylic acids as viral polymerase inhibitors App 20040106627 - Gardelli, Cristina ; et al. | 2004-06-03 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 